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contacted and 153 (66.5%) of them had accepted the HIV preliminary screen.
The confirmed test result reveal that the syphilis positive rate was 6.5% (nZ
10) and HIV positive rate was 10.5% (nZ 16). The reasons for partners to not
undergo screening included that they were the partner of previously diag-
nosed with HIV (n Z 24; 31.17%). There were 27.15% (41/151) of partners
or contactors who had used the recreational drug while having a sex. There
were 29 (70.73%) of partners or contactors recognized using the rush in the
past. We analyzed the community date only and founded that there were
592 preliminary HIV screenings had been completed. The HIV positive rate
was 6.58% (nZ 39). There were 12 (30.7%) cases called back to the counselor
to get the preliminary HIV positive result and 9 (75%) of them had the accom-
panying and arrangement by the counselor to the outpatient department and
accepted the Western Bolt test.
Conclusion: The community model of partner notification services provided
an advanced method for establishing the relationship with high risk cases
and therefore improved the overall effectiveness of partner notification and
contact tracing. It is suggested that the analysis to different partner notifica-
tion counseling for the cost-effectiveness could be done in the future.PS 1-039
INTERVENTIONS TO SUSTAIN ANTENATAL HIV SCREENING TAKE-UP RATE
J. M. Low A a, W. S. Lim B b, C. Y. Chong C c. aInfection Control Unit, KK
Women’s and Children’s Hospital, Singapore; bInfection Control Unit, KK
Women’s and Children’s Hospital, Singapore; cDepartment of Paediatric
Medicine, KK Women’s and Children’s Hospital, Singapore
Purpose: KKH embarked on a program of voluntary opt-in antenatal HIV
screening since August 1998 in order to decrease mother-to-child (MTC)
HIV transmission. The initial low antenatal HIV take-up rate led to a struc-
tured workflow from 2004 to increase the take-up rate. The aims of the
study are: to report the 1) antenatal HIV uptake rates, 2) pregnancy out-
comes of HIV positive mothers.
Methods: A baseline audit in February 2004 for HIV antenatal testing rates
was done. A new workflow was started in 2004 to incorporate HIV into the
routine opt-out antenatal screening package and counselling patients who
refused testing. HIV positive pregnant women were given antiretroviral
treatment (ART) antenatally, intrapartum and postnatally to the newborn.
In August 2010, an Infectious Diseases Resource Manager was recruited for
this project. Her roles included advising post-natal mothers not to breast-
feed and monitoring compliance to ART for the newborn.
Results: The baseline HIV take-up rate in 2004 was 38.1% (106 of 278). Post-
intervention, this improved to 99.7% - 100%. The most common reasons for
opting-out included: unnecessary testing, prior testing and refusal by hus-
band. HIV was positive in 0.14% (107 of 78151) antenatal patients. Pregnancy
outcomes for HIV positive patients were: 90 (84.1%) live births in Singapore,
1 (0.9%) delivery in mother’s native country, 6 (5.5%) terminations of preg-
nancy (TOP), 2 (1.9%) mid-trimester pregnancy terminations (MTPT), 3
(2.8%) lost to follow-up. Only 1 child (1/ 107, 0.9%) was infected with HIV
despite ART. There was no difference in age or nationality between patients
that underwent TOP/ MTPT versus live births. No long-term side-effects in
the uninfected children were seen on follow-up.
Conclusion: The structured workflow and counseling resulted in a high and
sustained HIV antenatal testing rate of 99.7% e 100% and decreased the
MTC transmission rate to 0.9%.PS 1-040
ACQUIRED IMMUNE DEFICIENCY SYNDROME WITH FATAL PNEUMONIA
PROBABLY CAUSED BY CYTOMEGALOVIRUS (CMV): A CASE REPORT
Mei-Miao Eu a, Wen-Liang Yu b. aDepartment of Infection Control
Committee, Taiwan; bDepartment of Intensive Care Medicine, Chi-Mei
Medical Center, Tainan, Taiwan
Purpose: Pneumocystis jiroveci pneumonia (PCP) is the most common infec-
tion in HIV patients with ground-glass opacities on chest film, however, cyto-
megalovirus (CMV) pneumonia may occur with similar features to PCP.
Case report: The 38 y/o man was generally well before but had taste distur-
bance (alteration of taste) for one month, thus causing poor appetite and loss
of 5-kg body weight in recent weeks. He had general malaise, fever and cough
with whitish sputum for 2 weeks. He came to our Emergent Room, wheretachycardia, normocytic anemia and increased C-reactive protein level
were noted. The chest film showed mixed alveolar and interstitial infiltration
over both lung fields. There was no headache, chest and abdominal pain,
nausea/vomiting, diarrhea, dysuria or tea-color urine. He was admitted
with suspected atypical pneumonia and received parenteral moxifloxacin.
But dyspnea and ground-glass interstitial infiltration worsened. Anti-HIV anti-
body and Western blot results were positive. CD4 count was 29/mL and CD4/
CD8 was 16%. He received intravenous sulfamethoxazole/trimethoprim (1200/
240 mg every 6 hours), minocycline (100mg every 12 hours) and imipenem (500
mg every 6 hours). He was intubated due to progressive hypoxemia on the
third hospitalized day, and parenteral hydrocortisone 100 mg every 8 hours
was added. The serology results of Mycoplasam, Chlamydia, Legionella and
Influenza A/B were all negative. Serial sputum cytology tests showed scat-
tered inflammatory cells without characteristic foamy alveolar exudate to
suggest PCP and the Gomori methenamine silver stains were negative. Combi-
vir and stocrit were added. However, profound shock and hypoxemia pro-
gressed and the patient died on the 9th day of hospitalization. The final
sputum PCR for CMV was positive, but the CMV antigenemia was negative.
Conclusions: CMV pneumonitis should be early considered in a HIV patient
with pneumonia as the clinical features could mimic PCP.PS 1-041
THE PREVALENCE OF GENOTYPE, RISK GROUPS, AND DRUG-RESISTANT
TO HAART IN TREATMENT NAI¨VE HIV-1 INFECTED PATIENTS IN
SOUTHERN TAIWAN, 2004 TO 2013
Yi-Li Shih a, Ya-Chien Hung a, Wei-Fang Chen a, Ya-Ting Yang a, Chung-
Hsu Lai a,b,c, Hsi-Hsun Lin b. aDivision of Infection Control Laboratory, E-Da
Hospital/I-Shou University, Kaohsiung City, Taiwan; bDivision of Infectious
Diseases, E-Da Hospital/I-Shou University, Kaohsiung City, Taiwan;
cGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical
University, Kaohsiung City, Taiwan
Purpose: The aim of this study is to investigation the prevalence of drug
resistance in treatment naı¨ve patients from 2004 to 2013.
Methods: A total of 283 cases were included. The drug-resistance was
detected by using TRUGENE HIV-1 Genotyping Assay (Siemens) for gene
amplification and GeneObjects software (version 4.1, Siemens) for analysis
of resistance associated mutation.
Results: Among the 283 patients, 255 (90.1%) were male, 154 (54.4%) were
intravenous drug user (IDU), 76 (26.9%) were men who have sex with men
(MSM), and 48 (17.0%) were heterosexuality. Genotype (GT)-CRF07_BC
(55.1%) was predominant in IDU (95.5%). GT-B (37.1%) was predominant in
MSM (71.4%) and heterosexuality (21.0%). GT-CRF01_AE (7.8%) was predom-
inant in heterosexuality (86.4%). Any drugs resistances were 6.4% (all geno-
type), 12.4% (GT- B), 2.6% (GT-CRF01_AE), and 4.6% (GT-CRF07_BC). The
resistant rates were 14.5% in MSM, 4.2% in heterosexuality, and 2.6% in
IDU. For the 18 drug-resistance cases, 4 (1.4%) had NRTIs resistance, 11
(3.9%) had NNRTIs resistance, 3 (1.1%) had resistance to both NRTIs and
NNRTIs, and none was resistant to PIs. The major mutation associated
with NRTIs resistance were M184V (42.9%) and K65R (28.6%), and NNRTIs
was K103N (57.1%).
Conclusions: The overall drug-resistant rate of HAARTs was 6.4% in treat-
ment naı¨ve HIV-1 infected patients. The resistant rate was higher in GT- B
and MSM.PS 1-042
STATINS AS ADD-ON THERAPY FOR CHRONIC HEPATITIS C: A META-
ANALYSIS
Aubrey Q. Taguba, M.D., Mara T. Panlilio, M.D., Margaret J. Villamayor, M.D.,
Janus P. Ong, M.D., Ma., Lourdez O. Daez, M.D. UP Philippine General
Hospital, Department of Medicine, Section of Gastroenterology
Purpose: The current standard therapy for chronic hepatitis C, the combina-
tion of pegylated interferon (PEG IFN) and ribavirin (RBV), has a 50% failure
rate in achieving sustained virologic response (SVR). The use of add-on pro-
tease inhibitors, such as boceprevir or telaprevir, results in SVR of as much as
70%; however, marked anemia, anorexia, and neutropenia have been re-
ported in the use of the triple regimen. This meta-analysis aims to determine
the efficacy and safety of statins as add-on therapy with PEG IFN and RBV for
chronic hepatitis C.
